Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

SGLT inhibition in T1DM — definite benefit with manageable risk

Nature Reviews Endocrinology volume 13, pages 698–699 (2017)Cite this article

Subjects

Two phase III trials using the selective SGLT2 inhibitor dapagliflozin or the dual SGLT2/SGLT1 inhibitor sotagliflozin in patients with type 1 diabetes mellitus show similar clinical benefit (reduction of HbA1c, body weight, blood pressure and insulin dose). The risk of hypoglycaemia and diabetic ketoacidosis with these inhibitors can be managed by careful adjustment of insulin therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ferrannini, E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 27–38 (2017).

    Article  CAS  Google Scholar 

  2. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  Google Scholar 

  3. Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

    Article  CAS  Google Scholar 

  4. Miller, K. M. et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 38, 971–978 (2015).

    Article  Google Scholar 

  5. Lyons, S. K. et al. Use of adjuvant pharmacotherapy: international comparison of 49,367 individuals in the diabetes rospective follow-up and T1D exchange registries. Diabetes Care 40, e139–e140 (2017).

    Article  Google Scholar 

  6. Dandona, P. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(17)30308-X (2017).

  7. Garg, S. K. et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1708337 (2017).

  8. Lapuerta, P. et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab. Vasc. Dis. Res. 12, 101–110 (2015).

    Article  CAS  Google Scholar 

  9. Rosenstock, J. & Ferrannini, E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015).

    Article  CAS  Google Scholar 

  10. Handelsman, Y. et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr. Pract. 22, 753–762 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CNR Institute of Clinical Physiology, Via Roma 67, Pisa, 56100, PI, Italy

    Ele Ferrannini

  2. Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, Pisa, I-56126, Italy

    Anna Solini

Authors
  1. Ele Ferrannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Solini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ele Ferrannini.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrannini, E., Solini, A. SGLT inhibition in T1DM — definite benefit with manageable risk. Nat Rev Endocrinol 13, 698–699 (2017). https://doi.org/10.1038/nrendo.2017.139

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2017.139

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing